Related Experiment Videos
What cardiologists do need to know about procalcitonin
Christian Mueller1, Mirjam Christ-Crain, Beat Müller
1Department of Internal Medicine, University Hospital Basel, Switzerland. chmueller@uhbs.ch
Clinical Laboratory
|February 22, 2005
Summary
Procalcitonin aids in diagnosing infective endocarditis (IE) and reduces antibiotic use in lower respiratory tract infections (LRTI). This biomarker shows high sensitivity and specificity for IE and safely decreases antibiotic prescriptions for LRTI.
Area of Science:
- Biomarkers in Infectious Diseases
- Clinical Microbiology
- Cardiology
Background:
- Infective endocarditis (IE) diagnosis is challenging due to varied presentations.
- Lower respiratory tract infections (LRTI) are often overtreated with antibiotics, contributing to resistance.
- Procalcitonin is a novel marker for systemic bacterial infections.
Purpose of the Study:
- To evaluate procalcitonin's utility in diagnosing IE.
- To assess the impact of procalcitonin-guided therapy on antibiotic use in LRTI.
Main Methods:
- Prospective cohort study of patients with suspected IE, comparing procalcitonin levels with final diagnoses.
- Analysis of procalcitonin's diagnostic accuracy (ROC curve, sensitivity, specificity, predictive values).
- Evaluation of a procalcitonin-based strategy to guide antibiotic treatment in LRTI patients.
Main Results:
- Procalcitonin levels were significantly higher in IE patients (median 6.56 µg/L) vs. non-IE (median 0.44 µg/L).
- Procalcitonin demonstrated superior diagnostic accuracy for IE (AUC 0.856) compared to C-reactive protein (AUC 0.657).
- Procalcitonin-guided therapy reduced antibiotic exposure in LRTI by 51% (adjusted relative risk 0.49) without compromising outcomes.
Conclusions:
- Procalcitonin is a valuable biomarker for diagnosing IE, with a suggested cutoff of 2.3 µg/L for optimal predictive accuracy.
- Procalcitonin-guided management safely and substantially reduces antibiotic usage in LRTI, addressing concerns of antibiotic resistance.